Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136341 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Annita-Ioanna Gkioka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Dexamethasone, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Greece and the European Union (European Social Fund-ESF).
Abstract (Originalsprache)
Serum cereblon (CRBN) has been proposed as a target protein for immunomodulatory drugs (IMiDs). IMiDs are one of the backbone treatment options in multiple myeloma (MM), rendering CRBN an intriguing candidate for use as a biomarker in clinical settings. Ninety-two (92) MM patients, mostly relapsed/refractory and a few at diagnosis, were included in the study, from lenalidomide–dexamethasone (LD) initiation until last follow-up or death. Median CRBN at LD initiation (N = 68) treatment was 247 pg/mL (range, 0–9760 pg/mL), at the time of best response (BR) status (N = 59) 142.5 pg/mL (range, 0–9940 pg/mL) and in patients with relapse/refractory MM to LD regimen (N = 54) 298 pg/mL (range, 0–9840 pg/mL). CRBN in healthy individuals was almost undetectable and significantly lower compared to the CRBN at LD initiation (p = 0.003), at BR to LD (p = 0.012) and at relapse to LD (p = 0.002). CRBN was significantly lower at BR in contrast to LD initiation and relapse to LD (p = 0.04, p = 0.028). High levels of CRBN at treatment initiation correlated with early relapse to LD (≤12 months) (p = 0.03). Seven-year survival was improved in patients with CRBN levels below median measured at the time of LD initiation (p = 0.013) as well as at BR (p = 0.032). CRBN was associated with treatment response and is predictive of survival after LD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Section of First Department of Propedeutic Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Annita-Ioanna Gkioka, Aspasia Koudouna
Förderung
- European Union
- Greece and the European Union (European Social Fund-ESF)
Zitieren
APA
Gkioka, A. I., Gkiokas, A., Papadatou-Gigante, M., Alexandropoulos, A., Tryfou, T. M., Koudouna, A., Bartzi, V., & Kyrtsonis, M. C. (2025). Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136341
Vancouver
Gkioka AI, Gkiokas A, Papadatou-Gigante M, Alexandropoulos A, Tryfou TM, Koudouna A, et al. Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136341
BibTeX
@article{Gkioka2025,
author = {Gkioka, Annita-Ioanna and Gkiokas, Alexandros and Papadatou-Gigante, Mavra and Alexandropoulos, Alexandros and Tryfou, Thomai-Marina and Koudouna, Aspasia and Bartzi, Vasiliki and Kyrtsonis, Marie-Christine},
title = {Serum Cereblon (CRBN) Levels Predict Long Term Post- Lenalidomide-Dexamethasone Survival in Multiple Myeloma (MM) Patients and Correlate with Disease Characteristics},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136341}
}
EUVIMED